Simian immunodeficiency virus antigen (SIV antigen) (SIV antigen)

Simian immunodeficiency virus (SIV) antigen refers to the various proteins encoded by the SIV genome, a lentivirus that naturally infects non-human primates and serves as the primary surrogate model for human HIV-1 infection (NIH, 2023). These antigens are categorized into structural proteins (Gag, Pol, and Env), regulatory proteins (Tat and Rev), and accessory proteins (Nef, Vif, Vpr, and Vpx), all of which are essential for the viral life cycle (UniProt, 2024). In therapeutic research, these antigens are the primary targets for vaccine candidates, such as the RhCMV-vector and Ad26-vector vaccines, which aim to induce protective T-cell and antibody responses (Hansen et al., 2011, Nature; Barouch et al., 2018, Lancet). These proteins facilitate viral attachment, membrane fusion, and the replication of the viral genome within host CD4+ T cells, leading to Simian Acquired Immunodeficiency Syndrome (SAIDS) (Pickering et al., 2016, Journal of Virology). Because SIV pathogenesis closely mirrors HIV in humans, these antigens are fundamental to testing the efficacy of novel biomedical preventions and curative strategies (Bournazos et al., 2019, Cell). Therapeutic approaches targeting these antigens aim to stimulate the host's immune system to recognize and destroy infected cells or to block the virus from entering new cells.

Other names

SIV proteinsSimian immunodeficiency virus polyproteinSIV structural proteinsSIV regulatory proteinsSIV accessory proteinsSIV Gag proteinSIV Env proteinSIV Pol protein

Vaccine-mediated induction of SIV-specific T-cell responses and B-cell responses to prevent viral acquisition or control viral replication (Hansen et al., 2011, Nature; Barouch et al., 2018, Lancet).